Diabytes
Sun Pharma Q4 net up 23% at Rs 1,011.56 cr
The company had posted net profit of Rs 820.21 crore in the same period previous fiscal, Sun Pharmaceutical Industries said in a filing to the BSE.
Trending Photos
5- 10
- 10
- 9
New Delhi: Sun Pharmaceutical Industries on Tuesday reported 23.32 percent increase in consolidated net profit for the fourth quarter ended March 31, 2013 at Rs 1,011.56 crore and also announced issue of bonus shares to existing shareholders.
The company had posted net profit of Rs 820.21 crore in the same period previous fiscal, Sun Pharmaceutical Industries said in a filing to the BSE.
Total income from operations during the quarter under review stood at Rs 3,087.04 crore as against Rs 2,336.18 crore in the year-ago period, it said.
For the fiscal 2012-13, consolidated net profit stood at Rs 3,008.06 crore as against Rs 2,656.69 crore in the previous fiscal.
Total income from operations for FY'13 was at Rs 11299.86 crore as against Rs 8,019.75 crore in FY'12, it said.
Commenting on the performance, Sun Pharma Managing Director Dilip Shanghvi said: "Our sales for FY13 have crossed the USD 2 billion mark. While it took us almost 27 years to record USD 1 billion in revenues, the next billion was added in just 3 years."
The company's businesses continue to perform in line with expectations, he said, adding Sun Pharma would continue to focus on building a differentiated and specialty product portfolio and enhancing international presence.
"Overall, we shall strive to remain focused on execution and building a business with consistent performance," Shanghvi added.
Sun Pharma said it will issue bonus shares to existing shareholders to mark completion of 30 years and crossing the USD 2 billion revenue milestone.
The Board of Directors at a meeting held today have recommended issue of bonus shares to existing shareholders in the ratio of 1:1 subject to the receipt of approval of the equity shareholders, it said.
The board has also recommended payment of a dividend of Rs 5 per equity share of face value Re 1 each, it added.
Elaborating the performance, the company said sale of branded prescription formulations in India was Rs 780 crore for the fourth quarter, accounting for 25 percent of total sales. For FY'13, sales were at Rs 2,966 crore accounting for 26 percent of total sales.
In the US, sales were at USD 330 million for Q4FY13, up by 63 percent. For FY'13, US sales were USD 1,132 million recording a growth of 56 percent.
Formulation sales in rest of the world (ROW) markets outside of India and US accounted for USD 73 million in Q4FY13 while for FY13, it was USD 281 million.
Shares of Sun Phara ended the day at Rs 995.55 per scrip, down 1.90 percent from the previous close on BSE.
PTI
The company had posted net profit of Rs 820.21 crore in the same period previous fiscal, Sun Pharmaceutical Industries said in a filing to the BSE.
Total income from operations during the quarter under review stood at Rs 3,087.04 crore as against Rs 2,336.18 crore in the year-ago period, it said.
For the fiscal 2012-13, consolidated net profit stood at Rs 3,008.06 crore as against Rs 2,656.69 crore in the previous fiscal.
Total income from operations for FY'13 was at Rs 11299.86 crore as against Rs 8,019.75 crore in FY'12, it said.
Commenting on the performance, Sun Pharma Managing Director Dilip Shanghvi said: "Our sales for FY13 have crossed the USD 2 billion mark. While it took us almost 27 years to record USD 1 billion in revenues, the next billion was added in just 3 years."
The company's businesses continue to perform in line with expectations, he said, adding Sun Pharma would continue to focus on building a differentiated and specialty product portfolio and enhancing international presence.
"Overall, we shall strive to remain focused on execution and building a business with consistent performance," Shanghvi added.
Sun Pharma said it will issue bonus shares to existing shareholders to mark completion of 30 years and crossing the USD 2 billion revenue milestone.
The Board of Directors at a meeting held today have recommended issue of bonus shares to existing shareholders in the ratio of 1:1 subject to the receipt of approval of the equity shareholders, it said.
The board has also recommended payment of a dividend of Rs 5 per equity share of face value Re 1 each, it added.
Elaborating the performance, the company said sale of branded prescription formulations in India was Rs 780 crore for the fourth quarter, accounting for 25 percent of total sales. For FY'13, sales were at Rs 2,966 crore accounting for 26 percent of total sales.
In the US, sales were at USD 330 million for Q4FY13, up by 63 percent. For FY'13, US sales were USD 1,132 million recording a growth of 56 percent.
Formulation sales in rest of the world (ROW) markets outside of India and US accounted for USD 73 million in Q4FY13 while for FY13, it was USD 281 million.
Shares of Sun Phara ended the day at Rs 995.55 per scrip, down 1.90 percent from the previous close on BSE.
PTI
 "DNA: PM Modi watches Surya Tilak of Shri Ram Lalla")
 "DNA: Inside story of 29 Naxalites' encounter")
 "DNA test of 'religious thinking' on UPSC list")
 "DNA: Did cloud seeding drown Dubai?")
 "DNA: Is Israel going to bring a big storm?")
 "DNA: The hidden dangers of protein powders")
 "DNA: Analysis of Mamata Banerjee's riot politics!")
 "DNA: Is Constitution going to be changed?")
 "DNA: Who is killing India's Enemies?")
 "DNA: Why did some Muslim countries appear to help Israel?")
